GH Research PLC
NASDAQ:GHRSBiotechnology
-$0.04 today
- Market cap
- $1.25B
- Beta
- 1.31
- P/E (TTM)
- -23.8
- EPS (TTM)
- -$0.91
Volume 0.46M
Average 0.23M
GHRS Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
GH Research PLCNASDAQ: GHRS
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses turns negative
Q1 FY2026 other income / expenses was -$219K, compared with $1.92M a year earlier. Trailing-twelve-month other income / expenses was $10.27M. Over 3 fiscal years it compounded at +15.3% a year.
Context
- Other income / expenses increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other income / expenses holds near -$219K or moves back toward the trailing-twelve-month quarterly average of $2.57M.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 12.42M USD
- Year-over-year change
- +9.4%
- 4-year CAGR
- +20.5%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.42M | +9.4% |
| FY2024 | 2024-12-31 | 11.35M | +101.4% |
| FY2023 | 2023-12-31 | 5.64M | -30.4% |
| FY2022 | 2022-12-31 | 8.1M | +37.3% |
| FY2021 | 2021-12-31 | 5.9M | — |
Other Income / Expenses vs competitors
How GHRS compares with its peers on the latest reported figures
- GHRS's LTM Mar 2026 other income / expenses of $10.27M is the 3rd highest of the 9 companies compared; the peer median is -$8.71M.
- Its year-over-year change of +9.2% is the 3rd highest of 8, against a peer median of -151.5%.
- Over three fiscal years its annual growth of +15.3% compares with a peer median of +28.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $14.93M | +11.7% | — | 74.6% |
| LTM Mar 2026 | $10.56M | +70.0% | +86.2% | — | |
| LTM Mar 2026 | $10.27M | +9.2% | +15.3% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $7.69M | — | — | — |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $745K | -95.5% | -4.3% | — |
| LTM Jun 2026 | -$18.16M | -151.5% | — | — | |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | -$83.33M | -392.9% | — | — |
| LTM Mar 2026 | -$129.21M | -2023.6% | +28.2% | — | |
| LTM Jun 2026 | -$359.21M | -1411.2% | — | — | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding GHRS) | -$8.71M | -151.5% | +28.2% | 74.6% | |
Competitors are the stored peer set for GHRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 335K |
| Gross Profit | 0 | 0 | 0 | 0 | (335K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 8.55M | 20.48M | 29.82M | 35.02M | 38.73M |
| Selling, General & Admin | 6.54M | 10.06M | 11.12M | 15M | 21.61M |
| Operating Expenses | 15.1M | 30.55M | 41.22M | 50.31M | 60.34M |
| Depreciation & Amortization | 19K | 47K | 315K | 315K | 335K |
| EBITDA | (9.17M) | (22.41M) | (35.21M) | (38.6M) | (47.46M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (15.1M) | (30.55M) | (41.22M) | (50.31M) | (60.68M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 9 | 858K | 1.89M | 2.63M | 2.63M |
| Interest Expense | 9K | — | 723K | 717K | 463K |
| Other Income / Expenses | 5.9M | 8.1M | 5.64M | 11.35M | 12.42M |
| Income Before Tax | (9.2M) | (22.46M) | (35.59M) | (38.96M) | (48.26M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (9.2M) | (22.46M) | (35.59M) | (38.96M) | (48.26M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.18) | (0.14) | (0.68) | (0.75) | (0.79) |
| EPS (Diluted) | (0.18) | (0.14) | (0.68) | (0.75) | (0.79) |
| Weighted Avg Shares | 52.02M | 52.02M | 52.02M | 52.03M | 61.04M |
| Weighted Avg Shares (Diluted) | 52.02M | 52.02M | 52.02M | 52.03M | 61.04M |
GH Research PLC
NASDAQ:GHRS
Intrinsic Alpha fair value
Locked
Current Price
$18.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.